Tension-Type Headache
Conditions
Brief summary
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache (TTH).
Detailed description
The study will be conducted in 4 periods (the Screening Period, the Run-In Period, the Double-Blind Treatment Period and the Follow-up Period) and 4 visits (the Screening Visit, Enrollment Visit, Randomization Visit and End-of-Study Visit). Screening Period- Eligible subjects who provide written informed consent to participate will have study assessments performed at the Screening. Run-In Period- The Run-In Period will last for at least 28 days. During the Run-In period, subjects will be assessed for frequency of headache, study compliance and to ensure they meet all required study criteria for randomization. Double-Blind Treatment Period- The Double-Blind Treatment Period (Treatment Period) will last up to 4 weeks or until a qualifying headache episode has occurred and been treated using the study drug, whichever occurs first. Follow-up Period- All subjects will return to the investigational site for this visit, regardless of whether they have treated a qualifying TTH with study medication. Subjects who have not treated a qualifying TTH with study drug during the Treatment Period will be asked to return study materials and undergo safety evaluations at the End-of-Study Visit and will be discharged from the study. Subjects who have treated a qualifying TTH with study drug during the Treatment Period will ingest a 140 mg dose of open-label TNX-201 at this visit and undergo urine and blood sample collection for 3 hours post-dose to characterize each subject's genetic metabolism and PK profile.
Interventions
DRUGTNX-201
TNX-201 capsule
DRUGPlacebo
Placebo capsule
Sponsors
Tonix Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Capable of reading and understanding English and able to provide written informed consent to participate. 2. Male or female adults ≥ 18 and \< 65 years of age at the time of Visit 1. 3. Body mass index (BMI) ≥ 18.5 and ≤ 45.0. 4. Greater than 1 year history of episodic tension-type headache with onset prior to 50 years of age. 5. History of tension-type headaches that typically last ≥ 4 hours if untreated. 6. History of 2-14 tension-type headaches per month for the last 3 months prior to Visit 1. 7. Diagnosis must comply with the International Headache Society (IHS) diagnostic criteria. 8. No significant ECG findings at Screening 9. If female, is either not of childbearing potential or is practicing a predefined medically acceptable method of birth control (hormonal methods, intrauterine device, double-barrier method, sexually-exclusive vasectomized male partner, same-sex relationship) throughout the study. 10. Willing and able to comply with all protocol-specified requirements.
Exclusion criteria
1. Known or suspected hypersensitivity to isometheptene mucate or any excipients used in the formulation. 2. Use of any excluded concomitant medications. 3. Current use of opiate analgesics. 4. Use of any prophylactic drug therapy for headache control within 4 weeks of screening (e.g., anticonvulsants, mood stabilizers, beta-blocker, antidepressants, muscle relaxants, botulinum toxin). Subjects taking any of these medications for an indication other than headache (e.g., a beta-blocker for hypertension) will require medical monitor's approval prior to initiation of the Run-In Period. 5. History of medication use for acute headache on ≥ 10 days per month on average during the 3 months prior to Visit 1. 6. Positive results for addictive substances (e.g., cocaine, phencyclidine (PCP), amphetamines, opiates) at Screening. 7. History of migraine that exceeds a mean of four attacks per month during the preceding calendar year. 8. Lifetime history of schizophrenia, schizoaffective disorder, bipolar I/II disorder, delusional disorder, or psychotic disorder not otherwise specified. 9. Chronic pain disorders requiring medical treatment with opioids, chronic daily use of NSAIDs at the time of screening 10. History of coronary artery disease, coronary vasospasm, aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud's syndrome). 11. Inadequately controlled hypertension or persistently elevated systolic blood pressure or diastolic blood pressure upon repeat assessment at screening or on the day of randomization. 12. Current history of two or more CAD risk factors at Screening (tobacco use, receiving anti-hypertensive medication for hypertension, high LDL cholesterol or low HDL cholesterol levels, family history of premature CAD, diabetes mellitus) 13. History cerebral vascular accident, transient ischemic attack, seizure disorders. 14. Other clinically significant cardiac disease. 15. History of concurrent illness that requires hospitalization within 30 days prior to Visit 1. 16. Current evidence of human immunodeficiency virus infection or clinically significant hepatitis B or C infection. 17. Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history. 18. Participation in another investigational trial during the 30 days prior to Visit 1 or during this trial. Subjects who have participated in non-interventional trials may be permitted to participate on a case-by-case basis after review with the Medical Monitor. 19. Women who are pregnant, breast-feeding, or planning to become pregnant during this trial. 20. Any other household member currently participating in a Tonix-sponsored study or family member or relative of investigative staff. 21. Any condition and/or medical history that would make the subject unsuitable for study participation and completion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Pain Free | 2 hours | Number of subjects pain free at 2 hours post-dose (Pain assessed by 4-point NRS, VAS, and binary yes/no question). 4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe; pain-free defined as score = 0. VAS: 0-100 scale, anchored by verbal anchors of No Pain (0) vs. Worst Imaginable Headache Pain (100). Pain-free was defined as a score \<= 5 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 15, 30, 60, 90 minutes and 4 hours post-dose | 4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe. VAS: 0-100 scale, No Pain vs. Worst Imaginable Headache Pain |
| Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period | 24-hour post-dose period | — |
| Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders) | 2 hours | The Carvalho Responder analysis refers to subjects with at least 2 categories of improvement in their VAS severity category (0-100 scale). VAS severity categories were defined as severe if between 52-100 inclusive, moderate between 31-51 inclusive, mild between 6-30 inclusive, and pain-free if less than 6. Therefore, a Carvalho responder was either a subject who had a VAS response classified as 'severe' at baseline and 'mild' or pain-free at the post-dose assessment time point, or a subject who had a VAS response classified as 'moderate' at baseline and pain-free at the post-dose assessment time point. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TNX-201 4 X 35 mg capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
TNX-201: TNX-201 capsule | 83 |
| Placebo 4 X placebo capsules to be taken orally with a minimum of 4 ounces of water when qualifying tension-type headache occurs
Placebo: Placebo capsule | 82 |
| Total | 165 |
Baseline characteristics
| Characteristic | TNX-201 | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 83 Participants | 82 Participants | 165 Participants |
| Sex: Female, Male Female | 74 Participants | 74 Participants | 148 Participants |
| Sex: Female, Male Male | 9 Participants | 8 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 5 / 78 | 6 / 73 |
| serious Total, serious adverse events | 0 / 78 | 0 / 73 |
Outcome results
Primary
Number of Subjects Pain Free
Number of subjects pain free at 2 hours post-dose (Pain assessed by 4-point NRS, VAS, and binary yes/no question). 4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe; pain-free defined as score = 0. VAS: 0-100 scale, anchored by verbal anchors of No Pain (0) vs. Worst Imaginable Headache Pain (100). Pain-free was defined as a score \<= 5
Time frame: 2 hours
Population: LOCF Analysis~8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TNX-201 | Number of Subjects Pain Free | Binary Response | 21 Participants |
| TNX-201 | Number of Subjects Pain Free | 4-Point NRS | 21 Participants |
| TNX-201 | Number of Subjects Pain Free | VAS | 20 Participants |
| Placebo | Number of Subjects Pain Free | Binary Response | 20 Participants |
| Placebo | Number of Subjects Pain Free | 4-Point NRS | 19 Participants |
| Placebo | Number of Subjects Pain Free | VAS | 21 Participants |
Secondary
Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question)
4-point NRS grades: 0=none, 1=mild, 2=moderate, 3=severe. VAS: 0-100 scale, No Pain vs. Worst Imaginable Headache Pain
Time frame: 15, 30, 60, 90 minutes and 4 hours post-dose
Population: LOCF Analysis~8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 4 Hours | 37 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 90 Minutes | 13 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 30 Minutes | 4 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 4 Hours | 37 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 15 Minutes | 1 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 15 Minutes | 2 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 90 Minutes | 13 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 30 Minutes | 4 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 30 Minutes | 3 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 60 Minutes | 8 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 60 Minutes | 9 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 90 Minutes | 13 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 60 Minutes | 8 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 4 Hours | 39 Participants |
| TNX-201 | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 15 Minutes | 1 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 4 Hours | 34 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 15 Minutes | 0 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 30 Minutes | 2 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 60 Minutes | 8 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 90 Minutes | 17 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | Binary Response : 4 Hours | 37 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 15 Minutes | 0 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 30 Minutes | 1 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 60 Minutes | 7 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 90 Minutes | 14 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | 4-Point NRS : 4 Hours | 35 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 15 Minutes | 0 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 30 Minutes | 2 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 60 Minutes | 5 Participants |
| Placebo | Number of Subjects Pain Free at 15, 30, 60, 90 Minutes and 4 Hours Post-dose (Pain Will be Assessed by 4-point NRS, VAS, and Binary Yes/no Question) | VAS : 90 Minutes | 13 Participants |
Secondary
Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period
Time frame: 24-hour post-dose period
Population: 8 subjects in the TNX-201 group and 10 subjects in the placebo group who did not take a dose during the double-blind treatment period and/or did not report data 2-hour post-dose were excluded from analyses.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TNX-201 | Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period | 16 Participants |
| Placebo | Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period | 15 Participants |
Secondary
Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders)
The Carvalho Responder analysis refers to subjects with at least 2 categories of improvement in their VAS severity category (0-100 scale). VAS severity categories were defined as severe if between 52-100 inclusive, moderate between 31-51 inclusive, mild between 6-30 inclusive, and pain-free if less than 6. Therefore, a Carvalho responder was either a subject who had a VAS response classified as 'severe' at baseline and 'mild' or pain-free at the post-dose assessment time point, or a subject who had a VAS response classified as 'moderate' at baseline and pain-free at the post-dose assessment time point.
Time frame: 2 hours
Population: Only subjects who were categorized as severe or moderate at baseline and have data reported at 2 hours were included in this analysis. All subjects who took rescue medication at or before 2 hours were considered non-responders.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TNX-201 | Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders) | 24 Participants |
| Placebo | Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders) | 24 Participants |